QUAD vs SRPT vs ACCO vs ENVA vs EBF

For growth investors, Enova International, Inc.

(ENVA) is the stronger pick with 18. 6% revenue growth year-over-year, versus -9. 4% for Quad/Graphics, Inc. (QUAD). ACCO Brands Corporation (ACCO) offers the better valuation at 9. 2x trailing P/E (4. 8x forward), making it the more compelling value choice. Analysts rate Quad/Graphics, Inc. (QUAD) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ACCO Brands Corporation (ACCO) is the cheapest at 9.

2x versus Enova International, Inc. at 14. 9x. On forward P/E, ACCO Brands Corporation is actually cheaper at 4. 8x.

Over the past 5 years, Enova International, Inc.

(ENVA) delivered a total return of +368. 1%, compared to -72. 1% for Sarepta Therapeutics, Inc. (SRPT). Over 10 years, the gap is even starker: ENVA returned +20. 3% versus ACCO's -35. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Ennis, Inc.

(EBF) is the lower-risk stock at 0. 53β versus Sarepta Therapeutics, Inc. 's 2. 02β — meaning SRPT is approximately 282% more volatile than EBF relative to the S&P 500. On balance sheet safety, Ennis, Inc. (EBF) carries a lower debt/equity ratio of 3% versus 3% for Quad/Graphics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Enova International, Inc.

(ENVA) is pulling ahead at 18. 6% versus -9. 4% for Quad/Graphics, Inc. (QUAD). On earnings-per-share growth, the picture is similar: Quad/Graphics, Inc. grew EPS 150. 5% year-over-year, compared to -404. 7% for Sarepta Therapeutics, Inc.. Over a 3-year CAGR, SRPT leads at 33. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Ennis, Inc.

(EBF) is the more profitable company, earning 10. 2% net margin versus -32. 5% for Sarepta Therapeutics, Inc. — meaning it keeps 10. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ENVA leads at 23. 5% versus -29. 9% for SRPT. At the gross margin level — before operating expenses — SRPT leads at 59. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ACCO Brands Corporation (ACCO) trades at 4.

8x forward P/E versus 13. 5x for Ennis, Inc. — 8. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ACCO: 97. 0% to $8. 00.

In this comparison, EBF (16.

9% yield), ACCO (7. 1% yield), QUAD (3. 8% yield) pay a dividend. SRPT, ENVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Ennis, Inc.

(EBF) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 53), 16. 9% yield). Sarepta Therapeutics, Inc. (SRPT) carries a higher beta of 2. 02 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (EBF: +79. 4%, SRPT: +18. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (QUAD (Industrials) and SRPT (Healthcare) and ACCO (Industrials) and ENVA (Financial Services) and EBF (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: QUAD is a small-cap deep-value stock; SRPT is a small-cap high-growth stock; ACCO is a small-cap deep-value stock; ENVA is a small-cap high-growth stock; EBF is a small-cap deep-value stock. QUAD, ACCO, EBF pay a dividend while SRPT, ENVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.